Onco-Inmunología Aplicada y Traslacional
O-I Traslacional
University of Texas MD Anderson Cancer Center
Houston, Estados UnidosPublicaciones en colaboración con investigadores/as de University of Texas MD Anderson Cancer Center (2)
2019
-
The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer
Journal of Thoracic Oncology, Vol. 14, Núm. 6, pp. 1046-1060